- Home
- DARE vs PIII Comparison
DARE vs PIII Comparison
Compare DARE & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- PIII
- Stock Information
- Founded
- DARE 2015
- PIII 2015
- Country
- DARE United States
- PIII United States
- Employees
- DARE N/A
- PIII N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- PIII Medical/Nursing Services
- Sector
- DARE Health Care
- PIII Health Care
- Exchange
- DARE Nasdaq
- PIII Nasdaq
- Market Cap
- DARE 26.3M
- PIII 21.4M
- IPO Year
- DARE N/A
- PIII N/A
- Fundamental
- Price
- DARE $2.38
- PIII $6.37
- Analyst Decision
- DARE Strong Buy
- PIII Buy
- Analyst Count
- DARE 3
- PIII 2
- Target Price
- DARE $12.50
- PIII $16.25
- AVG Volume (30 Days)
- DARE 40.1K
- PIII 5.1K
- Earning Date
- DARE 08-11-2025
- PIII 08-06-2025
- Dividend Yield
- DARE N/A
- PIII N/A
- EPS Growth
- DARE N/A
- PIII N/A
- EPS
- DARE N/A
- PIII N/A
- Revenue
- DARE $25,909.00
- PIII $1,485,192,000.00
- Revenue This Year
- DARE $99,756.91
- PIII N/A
- Revenue Next Year
- DARE $119.77
- PIII $6.01
- P/E Ratio
- DARE N/A
- PIII N/A
- Revenue Growth
- DARE N/A
- PIII 9.79
- 52 Week Low
- DARE $2.35
- PIII $6.00
- 52 Week High
- DARE $4.60
- PIII $32.54
- Technical
- Relative Strength Index (RSI)
- DARE 34.73
- PIII 33.55
- Support Level
- DARE $2.56
- PIII $6.00
- Resistance Level
- DARE $2.95
- PIII $6.35
- Average True Range (ATR)
- DARE 0.12
- PIII 0.22
- MACD
- DARE -0.05
- PIII 0.03
- Stochastic Oscillator
- DARE 8.45
- PIII 21.62
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.